2022China Nucleic Acid Drugs and New Vaccines Industry Conference
2022year8month18day-19day, byTaas LabsNucleic Acid Summit · hosted by Talkthink Biology2022The China Nucleic Acid Drugs and New Vaccines Industry Conference was held in Wuhan. This conference focused on the fields of nucleic acids and vaccines, with an emphasis on the market prospects and development trends of emerging therapies.RNAThe development challenges and pain points of nucleic acid drugs and vaccine drugs, integrating high-quality resources from home and abroad as well as the entire industry. From a professional perspective and with an eye on development, we aim to grasp the industry trend and promote innovation and development in the biotechnology industry. Frost & SullivanFrost & SullivanLiu Weiqi, Executive Director of Frost & Sullivan Greater China, was invited to attend the conference and discuss the current situation of the COVID-19 vaccine market andmRNADelivered a speech on the development trend of drugs.
Executive Director, Greater China, Frost & Sullivan Liu Weiqi
Liu Weiqi stated that the global COVID-19 situation remains severe, with domestic outbreaks occurring at multiple locations. New strains are emerging with stronger immune evasion and transmission rates. The new wave of epidemic spread has intensified the urgent need to improve vaccine coverage rates and vaccine iterations. Establishing a herd immunity barrier through vaccination can slow down the rate of virus mutation and protect high-risk populations. It remains the most effective measure in dealing with the normalization of the epidemic.
The vaccine industry chain is vertically integrated, involving multiple fields. It is characterized by wide coverage and numerous processes. The COVID-19 pandemic has driven rapid development in industries and enterprises with a high degree of association with the vaccine industry chain. "The high-end R&D and industrialization of vaccines in our country still heavily rely on imports for key instruments, equipment, raw materials, etc. Achieving high-quality domestic substitution will ensure the autonomy and controllability of the entire vaccine industry chain, enhancing the stability and competitiveness of the vaccine industry." Liu Weiqi said.
Currently, the global COVID-19 vaccine technology routes are showing a parallel development of multiple approaches. Among them, four vaccine types are developing at the fastest pace: inactivated vaccines, viral vector vaccines, recombinant protein vaccines,mRNAVaccines have brought more possibilities to the vaccine selection for recipients. The vaccines already on the market in China use inactivated vaccines, viral vector vaccines, and recombinant protein vaccines, with heterologous technologiesmRNAThe domestic research and development of the vaccine is still in the clinical stage, and it is expected to fill the current gap in this type of vaccine in China.
To meet the urgent needs of epidemic control, the development of COVID-19 vaccines has proceeded at an unprecedented pace in vaccine history. According to Liu Weiqi, under normal circumstances, the development process of vaccines is long, typically taking from identifying antigens to entering the market.10 - 15A year, while the COVID-19 vaccine has only been in use1Less than a year.
Data shows that there are already41The COVID-19 vaccine has been approved. Among them, subunit vaccines account for the largest proportion.11Including vaccinesWHOGlobal List of Essential Uses (GUEL)EUL"()),3Include domestic vaccinesEULCurrently, China already has7The COVID-19 vaccines approved for conditional marketing or emergency use are mostly inactivated vaccines. With mature technology and R&D production experience, the frequency of adverse reactions is relatively low.
In addition, China's pipeline of COVID-19 vaccines under development includes nebulized inhalation vaccines.mRNAVaccines account for the largest proportion, among which Aibo Biotech has made the most progress, with its products entering clinical trials.IIIIn the meantime, CanSino Biologics, which has already launched COVID-19 vaccine products, has also recently obtainedmRNAClinical approval document for COVID-19 vaccine.
Liu Weiqi pointed out that the COVID-19 pandemic has changed the competitive landscape of pharmaceutical companies.mRNAVaccines have made their way onto the historical stage, with excellent protection rates. TwomRNAVaccine sales far exceed those of other COVID-19 vaccines.2021yearCormirnatyGlobal sales reached a high of410Billions of dollars, and Pfizer has also used this to become the pharmaceutical company with the highest drug sales.
Subsequently, Liu Weiqi introduced to everyonemRNATrends in drug development.
He said, compared to traditional therapies,mRNAThe drug has unique advantages in terms of effectiveness, safety, flexibility, and production capacity, based onmRNAThe treatment platform has broad market prospects, asmRNAWith the advancement of therapy technology and enhanced stability, people aremRNAAs our understanding deepens, it will become an ideal platform for treating many disease areas.
"mRNADrug research, development, and production is a highly systematic discipline that integrates various fields. Compared to traditional drugs, upstream and downstream related industries have a more specialized division of labor. ' Liu Weiqi further stated. asmRNAThe continuous maturation of technology applications, as well as during the pandemicmRNAThe widespread use of vaccines has driven the vigorous development of upstream industrial chains, with businesses in various fields experiencing explosive growth. However, domesticallymRNAThe industrial chain is still in its infancy, and there are currently no absolute leading companies.
Looking at the global market, as of now, there are a total of3modelmRNAProduct launch,56modelmRNAThe drug has entered the clinical phase.
2020year12monthFDAApproved Pfizer andBioNtechandModernaTwomRNAThe emergency use of COVID-19 vaccines, with two vaccines being launched2021year2022The year was officially approved.2022year8monthModernaThe bivalent COVID-19 vaccinemRNA-1273.214Approved in the UK.
Already in clinical phasemRNAMedications, mainly concentrated in the vaccine field. In additionmRNAIn addition to the emergency launch of COVID-19 vaccines, most others are still in the early stages. Among them, tumor immunotherapy and the application of infectious vaccines in immunotherapy are the most numerous and mature. In addition, the development of delivery technologies will drivemRNAThe application of drugs in protein supplementation or replacement therapy has further expanded its indications.
Currently, there is no domestically approved product on the marketmRNAProducts, and those that have entered the clinical phase are less than10The indications are also concentrated on COVID-19.
Finally, Liu Weiqi concluded, 'AlthoughmRNAThere are still many challenges in the research and development of drugs, such asmRNAWith large molecular weights, higher immunogenicity, ease of degradation, and difficulties in delivery, etc., however, with the gradual maturation of technology applications, driven by factors such as the emergence of a large number of biotechnology companies and the capital market investment boom, we believe that futuremRNAThe expansion of the drug treatment field will continue, with both efficacy and safety being improved simultaneously. The R&D system is gradually becoming complete. With the trend towards cooperative commercialization, the upstream and downstream industries of the supply chain are expected to achieve rapid development. "
